[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576183":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":25,"responsibleParty":119,"collaborators":11,"id":121,"slug":11,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":11,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":11,"enrollmentInfo":129,"targetDuration":11,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Innate Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IPH4502 Monotherapy","EXPERIMENTAL",null,[13],"Drug: IPH4502",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","IPH4502","Part 1 (dose escalation) and Part 2 (dose optimization)",[9],[21],{"name":5,"role":22,"phone":23,"phoneExt":11,"email":24},"CONTACT","+33430303030","clinical.trials@innate-pharma.fr",[26,43,56,68,81,94,107],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Massachusetts General Hospital - Boston","RECRUITING","Boston","Massachusetts","02114","United States",{"type":34,"coordinates":35},"Point",[36,37],-71.05977,42.35843,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":11,"phoneExt":11,"email":11},"Leon Pappas, MD","PRINCIPAL_INVESTIGATOR",{"facility":44,"status":28,"city":45,"state":46,"zip":47,"country":32,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"John Theurer Cancer Center","Hackensack","New Jersey","07601",{"type":34,"coordinates":49},[50,51],-74.04347,40.88593,{"lat":51,"lon":50},[54],{"name":55,"role":42,"phone":11,"phoneExt":11,"email":11},"Martin Gutierrez, MD",{"facility":57,"status":28,"city":58,"state":58,"zip":59,"country":32,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Mount Sinai Tisch Cancer Center","New York","10029",{"type":34,"coordinates":61},[62,63],-74.00597,40.71427,{"lat":63,"lon":62},[66],{"name":67,"role":42,"phone":11,"phoneExt":11,"email":11},"Thomas Marron, MD",{"facility":69,"status":28,"city":70,"state":71,"zip":72,"country":32,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"NEXT Oncology - Dallas","Dallas","Texas","75039",{"type":34,"coordinates":74},[75,76],-96.80667,32.78306,{"lat":76,"lon":75},[79],{"name":80,"role":22,"phone":11,"phoneExt":11,"email":11},"Shiraj Sen, MD",{"facility":82,"status":28,"city":83,"state":84,"zip":85,"country":32,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"NEXT Oncology - Virginia","Fairfax","Virginia","22031",{"type":34,"coordinates":87},[88,89],-77.30637,38.84622,{"lat":89,"lon":88},[92],{"name":93,"role":22,"phone":11,"phoneExt":11,"email":11},"Alex Spira, MD",{"facility":95,"status":28,"city":96,"state":11,"zip":97,"country":98,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Centre Léon Bérard","Lyon","69008","France",{"type":34,"coordinates":100},[101,102],4.84789,45.74906,{"lat":102,"lon":101},[105],{"name":106,"role":42,"phone":11,"phoneExt":11,"email":11},"Armelle Vinceneux, MD",{"facility":108,"status":28,"city":109,"state":11,"zip":110,"country":98,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Gustave Roussy Cancer Institute","Villejuif","94805",{"type":34,"coordinates":112},[113,114],2.35992,48.7939,{"lat":114,"lon":113},[117],{"name":118,"role":42,"phone":11,"phoneExt":11,"email":11},"Yohann Loriot, MD",{"type":120,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100576183",false,"NCT06781983","Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors","A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors","Main Inclusion Criteria:\n\n* Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4\n* Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.\n* Measurable disease according to RECIST 1.1.\n* Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.\n* Adequate organ function and hematological function.\n\nMain Exclusion Criteria:\n\n* Known or suspected brain metastases.\n* Participants with an active infection, Any other infection requiring systemic treatment or latent infection.\n* Participants with clinically significant comorbidity(s).\n* History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.\n* Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.\n* Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.\n* Clinically significant cardiovascular disease and\u002For cardiac repolarization abnormality.\n* Participants with symptomatic heart failure, Acute coronary syndromes\n* Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.\n* Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.\n* Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.","ALL","18 Years",{"count":130,"type":131},145,"ESTIMATED","INTERVENTIONAL",[134],"PHASE1","This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4",[137],"Advanced or Metastatic Solid Tumors",[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153],"Exatecan","Topo-Isomerase I inhibitor","Squamous cell carcinoma of the head and neck","Esophageal squamous cell carcinoma","Triple negative breast cancer","Non-small cell lung cancer","Gastro-esophageal junction and gastric cancer","Colorectal carcinoma","Ovarian carcinoma","Prostate cancer","Cervical cancer","Melanoma","Urothelial carcinoma","Antibody-drug conjugates","ADC","2026-01-05",{"date":156,"type":157},"2026-01-07","ACTUAL",{"date":159,"type":157},"2025-01-24",{"date":161,"type":131},"2029-04",{"name":5,"class":6},7]